CytRx   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Los Angelos CA United States (1985)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
1997
NCT00004408
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chief Medical Officer, CytRx Corporation | CytRx Coorporation | CytRx Coporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Anemia, Sickle Cell (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Glioblastoma (Phase 2)

HIV Seropositivity (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Promyelocytic, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Motor Neuron Disease (Phase 2)

Neoplasms (Phase 1)

Pleural Effusion (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Prostatic Neoplasms (Phase 2)

Sarcoma (Phase 3)

Sarcoma, Kaposi (Phase 2)

Sclerosis (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 49
  • # of Trial APIs: 27